

Integrating HIV and TB services : operational research issues



TB/HIV workshop TAC/TAG June 2006

MÉDECINS SANS FRONTIÈRES




**SOUTH
AFRICA**

UNIVERSITY OF CAPE TOWN
School of Public Health and
Family Medicine



2. Estimated HIV prevalence in TB cases, 2002



The designations employed and the presentation of material on this map do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dashed lines represent approximate border lines for which there may not yet be full agreement.

TB :major cause of death in HIV+ adults in Africa

- Autopsy studies:
 - 32% Cote d'Ivoire
 - 38% Botswana
- Unrecognised

AIDS 1993;7:1569

Int J Tuberc Lung Dis 2002;6:55

How to improve diagnosis of HIV in TB patients ?

VCT or routine HIV testing in TB patients ?


Situation in Khayelitsha :

- 47 % (2003) to 91 % (end 2005)of TB patients counselled
- 86 % accept HIV test (Q4 05)
- Co-infection rate : 73 % (Khayelitsha 2006)
- Should an HIV test be part of the routine for Tb patients ?
 - No ?
 - Too many bad news together
 - Confidentiality
 - “ not ready”
 - YES ?
 - 65 to 75 % among TB patients are HIV (+) in Southern Africa
 - TB accelerates the course of HIV disease (VL + & CD4 -) ->early HIV diagnosis = early access to ARV treatment
 - Routine testing for TB patients = part of human right If availability of CD4/clinical screening and access to HAART ?

How to improve diagnosis of HIV in TB patients

-> do we need to walk out of voluntary counseling and testing (VCT) and advocate for routine testing in TB patients ?

“Are we not contributing to HIV stigma by adopting specific testing procedures like VCT” –Judge Edwin Cameron 2006



Source : Prof.Gary Maartens, Head Pharmacology, UCT.

Value of a sputum (-) result


Table 6. TB diagnosis of HIV patients (folder review)

	Smear (-ve)	Smear (+ve)	Total
Culture (+ve)	53	16	69
Culture (-ve)	38	2	40
	91	18	109

Smear sensitivity of 16% and a culture sensitivity of 63%.

Evolution of TB caseload in Khayelitha

(all TB patients regardless of HIV status)



Active TB research in HIV patients

- Systematic screening for indicative symptoms:
 - LOW (weight at every consultation),cough ,night sweats
- 2 sputum smears remain cornerstone
- If both negative, course of antibiotics (amoxicillin) and send 3rd sputum for CULTURE (nurse can request)
- Sensitivity tests in all re-treatment & failure cases
- CXR as part of routine screening
- > access to chest X-Ray
- > children : Mantoux test +gastric aspirate
- > Fn aspirate for suspected lymph nodes
- > access to US for suspicion of disseminated TB




A need for new nurse friendly TB diagnostic tests

- Improved sputum (induced)
- Liquid medium culture
- Phage assays (Fastplaque®)
- Immune response : γ -IFN production ESAT-6 & CFP-10)
- Nucleic acid amplification test

-> public private partnership
for R & D in TB test :

FIND

www.finddiagnostics.org



Visible results read by eye as plaques in a bacterial lawn(Left: negative result, Right: positive result)

How to improve treatment of HIV in TB patients ?

Assess optimal time to start antiretroviral therapy


Identify optimal antiretroviral regimens to use

Identify proper dose of ARVs in the presence of rifampicin


New TB drugs

Assess optimal time to start antiretroviral therapy

Time to death, by TB treatment status on start



Time to death, by TB treatment status and duration on start



20 % over-mortality when starting ARV during 1st month after initiating TB treatment

Source : A Boulle, K Hilderbrand


Identify optimal antiretroviral regimens to use

- Hepatitis
 - Rifampicine, INH, Pyrazinamide
 - Rash
 - Rifampicine, INH, Pyrazinamide
 - Peripheral neuropathy
 - INH
 - Nausea
 - Pyrazinamide
- Nevirapine , Efavirenz
 - Nevirapine , Efavirenz
 - D4t, DDI
 - AZT, DDI, PI

A need for new TB drugs

- Treatment shorter than 6 months
 - New resistance profile (emergence of MDR resistance)
 - ARV friendly
 - no induction of the P450 cytochrome
 - No common side effects
- > a public –private partnership : International TB alliance www.tballiance.org

TB incidence in patients on ARV vs non ARV in Khayelitsha



25% of patients on ARV will develop a TB within 3 years versus 60 % not on ARV
->HAART reduces TB incidence by 68 %-80 %

But ...



Still 12 % incidence rate among patient on ARV-> not good enough

(WHO emergency rate at 400/100.000 or 0.4 %)

Elucidate mechanisms to support adherence



Begin Treatment	5 tablets RIFA FOUR	2 Month SPUTUM CHECK	2 tablets of RIFINAH	5 Month SPUTUM CHECK	6 Months End Treatment
					
	For 2 Months: Monday to Friday		For 4 Months: Monday to Friday		



Operational Issues in the Integration of TB and HIV Care

How to improve TB and HIV services to patients

Determine ways to potentialize both services

- Integrate staff training
- Integrate service delivery
- Harmonize monitoring tools

**-> difficulties to accommodate differing TB and HIV
traditions and practices**


To pool TB and HIV staff and integrate training

- Integrated nursing staff in both TB and HIV care
- Tb and HIV staff should be able to rotate between services
 - > Improved staff morale with improved treatment outcomes
 - > New clinical career path for TB staff
 - > Renewed doctor's interest in TB



To integrate both monitoring system

- Rigidity of TB monitoring system
 - >TB cohort reporting system slowly adopted by HIV outcomes reports ->separate but similar registers
 - >Further integration of patient held records



To integrate services into a one stop service: what about the risk of nosocomial infection ?

- Is this risk increased compared to existing risk in a high incidence community ?
- Is this risk increased compared to inherent risk of HIV patients sitting together with undiagnosed TB/HIV patients
- How to design an appropriate architecture to reduce risk with obvious TB suspects ?



